nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—mammary gland—lung cancer	0.0349	0.212	CbGeAlD
Plerixafor—CXCR4—respiratory system—lung cancer	0.0233	0.141	CbGeAlD
Plerixafor—CXCR4—epithelium—lung cancer	0.0194	0.118	CbGeAlD
Plerixafor—CXCR4—bronchus—lung cancer	0.0192	0.116	CbGeAlD
Plerixafor—CXCR4—trachea—lung cancer	0.0172	0.104	CbGeAlD
Plerixafor—CXCR4—cardiac atrium—lung cancer	0.0162	0.0981	CbGeAlD
Plerixafor—CXCR4—bone marrow—lung cancer	0.0136	0.0829	CbGeAlD
Plerixafor—CXCR4—lung—lung cancer	0.0124	0.0751	CbGeAlD
Plerixafor—CXCR4—lymph node—lung cancer	0.00845	0.0513	CbGeAlD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—SOX2—lung cancer	0.00712	0.0182	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—NCAM1—lung cancer	0.00651	0.0167	CbGpPWpGaD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—CD4—lung cancer	0.0065	0.0166	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—ITGB1—lung cancer	0.00646	0.0165	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—OXTR—lung cancer	0.00592	0.0152	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ALDOA—lung cancer	0.00578	0.0148	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PXN—lung cancer	0.00546	0.014	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ABCG2—lung cancer	0.00546	0.014	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—FGR—lung cancer	0.0053	0.0136	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TF—lung cancer	0.00508	0.013	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—FGFR1—lung cancer	0.00505	0.0129	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ENO1—lung cancer	0.00487	0.0125	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ABCB1—lung cancer	0.00341	0.00873	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—SRC—lung cancer	0.00328	0.0084	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—PPIA—lung cancer	0.00327	0.00837	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—lung cancer	0.0032	0.00818	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KDR—lung cancer	0.00318	0.00814	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK3—lung cancer	0.00302	0.00774	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KIT—lung cancer	0.00293	0.0075	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—lung cancer	0.00292	0.00748	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—lung cancer	0.00292	0.00747	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—GRM8—lung cancer	0.00285	0.00731	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HIF1A—lung cancer	0.00279	0.00714	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—GRP—lung cancer	0.00279	0.00713	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—OXTR—lung cancer	0.00279	0.00713	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CREBBP—lung cancer	0.00228	0.00584	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—PPIA—lung cancer	0.00226	0.00578	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—GNG11—lung cancer	0.0022	0.00563	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—OXTR—lung cancer	0.00218	0.00559	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—lung cancer	0.00206	0.00529	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—ANXA1—lung cancer	0.00205	0.00525	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—AKT1—lung cancer	0.00204	0.00522	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GIPR—lung cancer	0.00203	0.0052	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CG—lung cancer	0.00203	0.00519	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—ADCY1—lung cancer	0.00198	0.00507	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—APP—lung cancer	0.00194	0.00498	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.00187	0.00479	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.00187	0.00479	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—ERCC2—lung cancer	0.00174	0.00447	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—ANXA1—lung cancer	0.00173	0.00443	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GRM8—lung cancer	0.00173	0.00443	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—JUN—lung cancer	0.00168	0.00431	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—APP—lung cancer	0.00164	0.0042	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MTOR—lung cancer	0.00155	0.00398	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CB—lung cancer	0.00155	0.00398	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EP300—lung cancer	0.00155	0.00397	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CD4—lung cancer	0.00155	0.00397	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—lung cancer	0.00152	0.00389	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—AVP—lung cancer	0.00151	0.00387	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—lung cancer	0.00147	0.00376	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GRP—lung cancer	0.00142	0.00364	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—OXTR—lung cancer	0.00142	0.00364	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00137	0.00352	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—lung cancer	0.00135	0.00346	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GNG11—lung cancer	0.00133	0.00341	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.0013	0.00334	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—SRC—lung cancer	0.00124	0.00319	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—ERCC2—lung cancer	0.00121	0.00309	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—lung cancer	0.0012	0.00307	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GIPR—lung cancer	0.00115	0.00294	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PTHLH—lung cancer	0.00111	0.00285	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—CD4—lung cancer	0.00105	0.0027	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—ANXA1—lung cancer	0.00105	0.00268	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GIPR—lung cancer	0.00104	0.00267	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.00101	0.0026	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—POMC—lung cancer	0.001	0.00257	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—APP—lung cancer	0.000992	0.00254	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GRM8—lung cancer	0.000976	0.0025	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—lung cancer	0.000946	0.00242	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—lung cancer	0.000938	0.0024	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRM8—lung cancer	0.000887	0.00227	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PGAM1—lung cancer	0.00088	0.00225	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—POMC—lung cancer	0.000847	0.00217	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SDC4—lung cancer	0.000821	0.0021	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AXL—lung cancer	0.000813	0.00208	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GRP—lung cancer	0.000804	0.00206	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—OXTR—lung cancer	0.000804	0.00206	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—lung cancer	0.000777	0.00199	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—lung cancer	0.000773	0.00198	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—AVP—lung cancer	0.000772	0.00198	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GNG11—lung cancer	0.000753	0.00193	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRP—lung cancer	0.00073	0.00187	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—OXTR—lung cancer	0.00073	0.00187	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—CD4—lung cancer	0.000728	0.00186	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SKI—lung cancer	0.000724	0.00186	CbGpPWpGaD
Plerixafor—CXCR4—Disease—B4GALT5—lung cancer	0.000703	0.0018	CbGpPWpGaD
Plerixafor—Vomiting—Topotecan—lung cancer	0.000685	0.00154	CcSEcCtD
Plerixafor—Malaise—Paclitaxel—lung cancer	0.000685	0.00154	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GNG11—lung cancer	0.000683	0.00175	CbGpPWpGaD
Plerixafor—Paraesthesia—Irinotecan—lung cancer	0.000682	0.00153	CcSEcCtD
Plerixafor—Syncope—Paclitaxel—lung cancer	0.000681	0.00153	CcSEcCtD
Plerixafor—Loss of consciousness—Etoposide—lung cancer	0.00068	0.00153	CcSEcCtD
Plerixafor—Rash—Topotecan—lung cancer	0.000679	0.00153	CcSEcCtD
Plerixafor—Hypersensitivity—Vinorelbine—lung cancer	0.000679	0.00152	CcSEcCtD
Plerixafor—Dermatitis—Topotecan—lung cancer	0.000678	0.00152	CcSEcCtD
Plerixafor—Vomiting—Erlotinib—lung cancer	0.000677	0.00152	CcSEcCtD
Plerixafor—Dyspnoea—Irinotecan—lung cancer	0.000677	0.00152	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ADCY1—lung cancer	0.000677	0.00173	CbGpPWpGaD
Plerixafor—Nervous system disorder—Cisplatin—lung cancer	0.000676	0.00152	CcSEcCtD
Plerixafor—Headache—Topotecan—lung cancer	0.000675	0.00152	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000674	0.00151	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000673	0.00172	CbGpPWpGaD
Plerixafor—Rash—Erlotinib—lung cancer	0.000672	0.00151	CcSEcCtD
Plerixafor—Dermatitis—Erlotinib—lung cancer	0.000671	0.00151	CcSEcCtD
Plerixafor—Skin disorder—Cisplatin—lung cancer	0.00067	0.00151	CcSEcCtD
Plerixafor—Insomnia—Gemcitabine—lung cancer	0.000669	0.0015	CcSEcCtD
Plerixafor—Dyspepsia—Irinotecan—lung cancer	0.000669	0.0015	CcSEcCtD
Plerixafor—Immune system disorder—Docetaxel—lung cancer	0.000668	0.0015	CcSEcCtD
Plerixafor—Headache—Erlotinib—lung cancer	0.000667	0.0015	CcSEcCtD
Plerixafor—Loss of consciousness—Paclitaxel—lung cancer	0.000667	0.0015	CcSEcCtD
Plerixafor—Hyperhidrosis—Cisplatin—lung cancer	0.000667	0.0015	CcSEcCtD
Plerixafor—Paraesthesia—Gemcitabine—lung cancer	0.000664	0.00149	CcSEcCtD
Plerixafor—Asthenia—Vinorelbine—lung cancer	0.000661	0.00148	CcSEcCtD
Plerixafor—Dyspnoea—Gemcitabine—lung cancer	0.00066	0.00148	CcSEcCtD
Plerixafor—Nausea—Vinblastine—lung cancer	0.000658	0.00148	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Irinotecan—lung cancer	0.000656	0.00147	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—lung cancer	0.000655	0.00168	CbGpPWpGaD
Plerixafor—Fatigue—Irinotecan—lung cancer	0.000655	0.00147	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000655	0.00147	CcSEcCtD
Plerixafor—Pruritus—Vinorelbine—lung cancer	0.000652	0.00146	CcSEcCtD
Plerixafor—Discomfort—Etoposide—lung cancer	0.000651	0.00146	CcSEcCtD
Plerixafor—Pain—Irinotecan—lung cancer	0.00065	0.00146	CcSEcCtD
Plerixafor—Constipation—Irinotecan—lung cancer	0.00065	0.00146	CcSEcCtD
Plerixafor—Mental disorder—Docetaxel—lung cancer	0.000648	0.00146	CcSEcCtD
Plerixafor—Arthralgia—Paclitaxel—lung cancer	0.000646	0.00145	CcSEcCtD
Plerixafor—Erythema—Docetaxel—lung cancer	0.000643	0.00145	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000642	0.00144	CcSEcCtD
Plerixafor—Nausea—Topotecan—lung cancer	0.00064	0.00144	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000639	0.00144	CcSEcCtD
Plerixafor—Discomfort—Paclitaxel—lung cancer	0.000639	0.00143	CcSEcCtD
Plerixafor—Abdominal discomfort—Methotrexate—lung cancer	0.000638	0.00143	CcSEcCtD
Plerixafor—Fatigue—Gemcitabine—lung cancer	0.000638	0.00143	CcSEcCtD
Plerixafor—Pain—Gemcitabine—lung cancer	0.000633	0.00142	CcSEcCtD
Plerixafor—Constipation—Gemcitabine—lung cancer	0.000633	0.00142	CcSEcCtD
Plerixafor—Nausea—Erlotinib—lung cancer	0.000633	0.00142	CcSEcCtD
Plerixafor—Dry mouth—Paclitaxel—lung cancer	0.000632	0.00142	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—COL4A2—lung cancer	0.000632	0.00162	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Etoposide—lung cancer	0.000632	0.00142	CcSEcCtD
Plerixafor—Diarrhoea—Vinorelbine—lung cancer	0.00063	0.00142	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PTHLH—lung cancer	0.000629	0.00161	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PXN—lung cancer	0.000629	0.00161	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000628	0.00141	CcSEcCtD
Plerixafor—Feeling abnormal—Irinotecan—lung cancer	0.000626	0.00141	CcSEcCtD
Plerixafor—Gastrointestinal pain—Irinotecan—lung cancer	0.000621	0.0014	CcSEcCtD
Plerixafor—Anaphylactic shock—Paclitaxel—lung cancer	0.00062	0.00139	CcSEcCtD
Plerixafor—Paraesthesia—Cisplatin—lung cancer	0.000619	0.00139	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GIPR—lung cancer	0.000616	0.00158	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKR1C1—lung cancer	0.000616	0.00158	CbGpPWpGaD
Plerixafor—Dyspnoea—Cisplatin—lung cancer	0.000615	0.00138	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ADCY1—lung cancer	0.000614	0.00157	CbGpPWpGaD
Plerixafor—Skin disorder—Etoposide—lung cancer	0.000614	0.00138	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—lung cancer	0.000611	0.00137	CcSEcCtD
Plerixafor—Feeling abnormal—Gemcitabine—lung cancer	0.00061	0.00137	CcSEcCtD
Plerixafor—Shock—Paclitaxel—lung cancer	0.00061	0.00137	CcSEcCtD
Plerixafor—Dizziness—Vinorelbine—lung cancer	0.000609	0.00137	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—lung cancer	0.000609	0.00137	CcSEcCtD
Plerixafor—Nervous system disorder—Paclitaxel—lung cancer	0.000608	0.00137	CcSEcCtD
Plerixafor—Skin disorder—Paclitaxel—lung cancer	0.000602	0.00135	CcSEcCtD
Plerixafor—Abdominal pain—Irinotecan—lung cancer	0.000601	0.00135	CcSEcCtD
Plerixafor—Hyperhidrosis—Paclitaxel—lung cancer	0.000599	0.00135	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PPP2R1B—lung cancer	0.000599	0.00153	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Cisplatin—lung cancer	0.000595	0.00134	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ANXA1—lung cancer	0.000591	0.00152	CbGpPWpGaD
Plerixafor—Pain—Cisplatin—lung cancer	0.00059	0.00133	CcSEcCtD
Plerixafor—Vomiting—Vinorelbine—lung cancer	0.000586	0.00132	CcSEcCtD
Plerixafor—Rash—Vinorelbine—lung cancer	0.000581	0.0013	CcSEcCtD
Plerixafor—Dermatitis—Vinorelbine—lung cancer	0.00058	0.0013	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—lung cancer	0.00058	0.0013	CcSEcCtD
Plerixafor—Headache—Vinorelbine—lung cancer	0.000577	0.0013	CcSEcCtD
Plerixafor—Syncope—Docetaxel—lung cancer	0.000577	0.0013	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SDC4—lung cancer	0.000575	0.00147	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTHLH—lung cancer	0.000571	0.00146	CbGpPWpGaD
Plerixafor—Feeling abnormal—Cisplatin—lung cancer	0.000568	0.00128	CcSEcCtD
Plerixafor—Paraesthesia—Etoposide—lung cancer	0.000567	0.00127	CcSEcCtD
Plerixafor—CXCR4—Disease—NPPA—lung cancer	0.000567	0.00145	CbGpPWpGaD
Plerixafor—Loss of consciousness—Docetaxel—lung cancer	0.000566	0.00127	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000564	0.00127	CcSEcCtD
Plerixafor—Dyspnoea—Etoposide—lung cancer	0.000563	0.00127	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DUSP3—lung cancer	0.000563	0.00144	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—APP—lung cancer	0.000561	0.00144	CbGpPWpGaD
Plerixafor—Insomnia—Paclitaxel—lung cancer	0.00056	0.00126	CcSEcCtD
Plerixafor—Hypersensitivity—Irinotecan—lung cancer	0.00056	0.00126	CcSEcCtD
Plerixafor—Paraesthesia—Paclitaxel—lung cancer	0.000556	0.00125	CcSEcCtD
Plerixafor—CXCR4—Disease—PPIA—lung cancer	0.000553	0.00142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RHEB—lung cancer	0.000552	0.00142	CbGpPWpGaD
Plerixafor—Dyspnoea—Paclitaxel—lung cancer	0.000552	0.00124	CcSEcCtD
Plerixafor—CXCR4—Disease—ALDOA—lung cancer	0.000549	0.00141	CbGpPWpGaD
Plerixafor—Arthralgia—Docetaxel—lung cancer	0.000548	0.00123	CcSEcCtD
Plerixafor—Nausea—Vinorelbine—lung cancer	0.000547	0.00123	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Etoposide—lung cancer	0.000546	0.00123	CcSEcCtD
Plerixafor—Dyspepsia—Paclitaxel—lung cancer	0.000545	0.00123	CcSEcCtD
Plerixafor—Asthenia—Irinotecan—lung cancer	0.000545	0.00122	CcSEcCtD
Plerixafor—Fatigue—Etoposide—lung cancer	0.000545	0.00122	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000544	0.00122	CcSEcCtD
Plerixafor—Pain—Etoposide—lung cancer	0.00054	0.00121	CcSEcCtD
Plerixafor—Constipation—Etoposide—lung cancer	0.00054	0.00121	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ANXA1—lung cancer	0.000537	0.00138	CbGpPWpGaD
Plerixafor—Dry mouth—Docetaxel—lung cancer	0.000536	0.0012	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—lung cancer	0.000535	0.0012	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000535	0.0012	CcSEcCtD
Plerixafor—Fatigue—Paclitaxel—lung cancer	0.000534	0.0012	CcSEcCtD
Plerixafor—Haemorrhage—Methotrexate—lung cancer	0.000533	0.0012	CcSEcCtD
Plerixafor—Asthenia—Gemcitabine—lung cancer	0.000531	0.00119	CcSEcCtD
Plerixafor—Pain—Paclitaxel—lung cancer	0.00053	0.00119	CcSEcCtD
Plerixafor—Constipation—Paclitaxel—lung cancer	0.00053	0.00119	CcSEcCtD
Plerixafor—Anaphylactic shock—Docetaxel—lung cancer	0.000525	0.00118	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GRM8—lung cancer	0.000524	0.00134	CbGpPWpGaD
Plerixafor—Pruritus—Gemcitabine—lung cancer	0.000524	0.00118	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000521	0.00133	CbGpPWpGaD
Plerixafor—Feeling abnormal—Etoposide—lung cancer	0.000521	0.00117	CcSEcCtD
Plerixafor—Diarrhoea—Irinotecan—lung cancer	0.00052	0.00117	CcSEcCtD
Plerixafor—CXCR4—Disease—ADCY1—lung cancer	0.000518	0.00133	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Etoposide—lung cancer	0.000517	0.00116	CcSEcCtD
Plerixafor—Shock—Docetaxel—lung cancer	0.000517	0.00116	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—lung cancer	0.000515	0.00116	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—POMC—lung cancer	0.000513	0.00131	CbGpPWpGaD
Plerixafor—Feeling abnormal—Paclitaxel—lung cancer	0.000511	0.00115	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—lung cancer	0.00051	0.00115	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—APP—lung cancer	0.000509	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ENO2—lung cancer	0.000508	0.0013	CbGpPWpGaD
Plerixafor—Hypersensitivity—Cisplatin—lung cancer	0.000508	0.00114	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SKI—lung cancer	0.000507	0.0013	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Paclitaxel—lung cancer	0.000507	0.00114	CcSEcCtD
Plerixafor—Diarrhoea—Gemcitabine—lung cancer	0.000506	0.00114	CcSEcCtD
Plerixafor—CXCR4—Disease—PPP2R1B—lung cancer	0.000505	0.00129	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SMARCA4—lung cancer	0.000505	0.00129	CbGpPWpGaD
Plerixafor—Dizziness—Irinotecan—lung cancer	0.000502	0.00113	CcSEcCtD
Plerixafor—Urticaria—Etoposide—lung cancer	0.000502	0.00113	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—lung cancer	0.000499	0.00112	CcSEcCtD
Plerixafor—Asthenia—Cisplatin—lung cancer	0.000495	0.00111	CcSEcCtD
Plerixafor—Urticaria—Paclitaxel—lung cancer	0.000492	0.00111	CcSEcCtD
Plerixafor—Abdominal pain—Paclitaxel—lung cancer	0.00049	0.0011	CcSEcCtD
Plerixafor—Vomiting—Irinotecan—lung cancer	0.000483	0.00109	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—lung cancer	0.000481	0.00108	CcSEcCtD
Plerixafor—Rash—Irinotecan—lung cancer	0.000479	0.00108	CcSEcCtD
Plerixafor—Dermatitis—Irinotecan—lung cancer	0.000479	0.00108	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000478	0.00108	CcSEcCtD
Plerixafor—Headache—Irinotecan—lung cancer	0.000476	0.00107	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—lung cancer	0.000475	0.00107	CcSEcCtD
Plerixafor—Diarrhoea—Cisplatin—lung cancer	0.000472	0.00106	CcSEcCtD
Plerixafor—Paraesthesia—Docetaxel—lung cancer	0.000472	0.00106	CcSEcCtD
Plerixafor—Vomiting—Gemcitabine—lung cancer	0.00047	0.00106	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—lung cancer	0.000468	0.00105	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—lung cancer	0.000467	0.00105	CcSEcCtD
Plerixafor—Rash—Gemcitabine—lung cancer	0.000467	0.00105	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—lung cancer	0.000466	0.00105	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—lung cancer	0.000466	0.00105	CcSEcCtD
Plerixafor—Erythema—Methotrexate—lung cancer	0.000464	0.00104	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—lung cancer	0.000464	0.00104	CcSEcCtD
Plerixafor—Headache—Gemcitabine—lung cancer	0.000464	0.00104	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—lung cancer	0.000462	0.00104	CcSEcCtD
Plerixafor—CXCR4—Disease—ENO1—lung cancer	0.000462	0.00118	CbGpPWpGaD
Plerixafor—Haemorrhage—Doxorubicin—lung cancer	0.000461	0.00104	CcSEcCtD
Plerixafor—Hypersensitivity—Paclitaxel—lung cancer	0.000456	0.00103	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—lung cancer	0.000453	0.00102	CcSEcCtD
Plerixafor—Asthenia—Etoposide—lung cancer	0.000453	0.00102	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—lung cancer	0.000453	0.00102	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—lung cancer	0.000453	0.00102	CcSEcCtD
Plerixafor—Nausea—Irinotecan—lung cancer	0.000451	0.00101	CcSEcCtD
Plerixafor—Constipation—Docetaxel—lung cancer	0.000449	0.00101	CcSEcCtD
Plerixafor—Pain—Docetaxel—lung cancer	0.000449	0.00101	CcSEcCtD
Plerixafor—Pruritus—Etoposide—lung cancer	0.000447	0.001	CcSEcCtD
Plerixafor—Asthenia—Paclitaxel—lung cancer	0.000444	0.000999	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PXN—lung cancer	0.00044	0.00113	CbGpPWpGaD
Plerixafor—Nausea—Gemcitabine—lung cancer	0.00044	0.000988	CcSEcCtD
Plerixafor—Vomiting—Cisplatin—lung cancer	0.000439	0.000985	CcSEcCtD
Plerixafor—Pruritus—Paclitaxel—lung cancer	0.000438	0.000985	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—AVP—lung cancer	0.000436	0.00112	CbGpPWpGaD
Plerixafor—Rash—Cisplatin—lung cancer	0.000435	0.000977	CcSEcCtD
Plerixafor—Dermatitis—Cisplatin—lung cancer	0.000434	0.000976	CcSEcCtD
Plerixafor—Feeling abnormal—Docetaxel—lung cancer	0.000433	0.000972	CcSEcCtD
Plerixafor—Diarrhoea—Etoposide—lung cancer	0.000432	0.000971	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1C1—lung cancer	0.000431	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—OXTR—lung cancer	0.000431	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRP—lung cancer	0.000431	0.0011	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Methotrexate—lung cancer	0.00043	0.000967	CcSEcCtD
Plerixafor—CXCR4—Disease—APP—lung cancer	0.00043	0.0011	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Docetaxel—lung cancer	0.000429	0.000965	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF9—lung cancer	0.000426	0.00109	CbGpPWpGaD
Plerixafor—Diarrhoea—Paclitaxel—lung cancer	0.000424	0.000953	CcSEcCtD
Plerixafor—Malaise—Methotrexate—lung cancer	0.000418	0.00094	CcSEcCtD
Plerixafor—Dizziness—Etoposide—lung cancer	0.000418	0.000939	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—lung cancer	0.000417	0.000936	CcSEcCtD
Plerixafor—Abdominal pain—Docetaxel—lung cancer	0.000415	0.000933	CcSEcCtD
Plerixafor—Dizziness—Paclitaxel—lung cancer	0.00041	0.000921	CcSEcCtD
Plerixafor—Nausea—Cisplatin—lung cancer	0.00041	0.000921	CcSEcCtD
Plerixafor—CXCR4—Disease—JUNB—lung cancer	0.000407	0.00104	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—lung cancer	0.000404	0.000908	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GNG11—lung cancer	0.000404	0.00103	CbGpPWpGaD
Plerixafor—Vomiting—Etoposide—lung cancer	0.000402	0.000903	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—lung cancer	0.000402	0.000902	CcSEcCtD
Plerixafor—Rash—Etoposide—lung cancer	0.000398	0.000895	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—lung cancer	0.000398	0.000894	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—lung cancer	0.000397	0.00102	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AVP—lung cancer	0.000396	0.00101	CbGpPWpGaD
Plerixafor—Headache—Etoposide—lung cancer	0.000396	0.000889	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—lung cancer	0.000396	0.000889	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—lung cancer	0.000395	0.000887	CcSEcCtD
Plerixafor—Vomiting—Paclitaxel—lung cancer	0.000394	0.000885	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000392	0.000881	CcSEcCtD
Plerixafor—Rash—Paclitaxel—lung cancer	0.000391	0.000878	CcSEcCtD
Plerixafor—Dermatitis—Paclitaxel—lung cancer	0.00039	0.000877	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—lung cancer	0.00039	0.000877	CcSEcCtD
Plerixafor—Headache—Paclitaxel—lung cancer	0.000388	0.000872	CcSEcCtD
Plerixafor—Hypersensitivity—Docetaxel—lung cancer	0.000387	0.000869	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—VEGFC—lung cancer	0.000384	0.000985	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Methotrexate—lung cancer	0.000378	0.00085	CcSEcCtD
Plerixafor—Asthenia—Docetaxel—lung cancer	0.000377	0.000847	CcSEcCtD
Plerixafor—Nausea—Etoposide—lung cancer	0.000375	0.000843	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—lung cancer	0.000373	0.000837	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—lung cancer	0.000372	0.000835	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—lung cancer	0.000371	0.000834	CcSEcCtD
Plerixafor—Nausea—Paclitaxel—lung cancer	0.000368	0.000827	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—lung cancer	0.000368	0.000826	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—lung cancer	0.000366	0.000822	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ADCY1—lung cancer	0.000363	0.00093	CbGpPWpGaD
Plerixafor—Malaise—Doxorubicin—lung cancer	0.000362	0.000814	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—lung cancer	0.00036	0.000809	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—lung cancer	0.000359	0.000807	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO3—lung cancer	0.000356	0.000913	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PPP2R1B—lung cancer	0.000354	0.000906	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SMARCA4—lung cancer	0.000354	0.000906	CbGpPWpGaD
Plerixafor—Loss of consciousness—Doxorubicin—lung cancer	0.000353	0.000793	CcSEcCtD
Plerixafor—Dizziness—Docetaxel—lung cancer	0.000347	0.00078	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000345	0.000775	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—lung cancer	0.000342	0.000769	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—lung cancer	0.000342	0.000768	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSPB1—lung cancer	0.000341	0.000874	CbGpPWpGaD
Plerixafor—Paraesthesia—Methotrexate—lung cancer	0.00034	0.000764	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00034	0.000763	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—lung cancer	0.000338	0.000759	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTHLH—lung cancer	0.000337	0.000864	CbGpPWpGaD
Plerixafor—Dyspnoea—Methotrexate—lung cancer	0.000337	0.000758	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—lung cancer	0.000334	0.000751	CcSEcCtD
Plerixafor—Vomiting—Docetaxel—lung cancer	0.000334	0.00075	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—lung cancer	0.000333	0.000749	CcSEcCtD
Plerixafor—Rash—Docetaxel—lung cancer	0.000331	0.000744	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—lung cancer	0.000331	0.000743	CcSEcCtD
Plerixafor—Headache—Docetaxel—lung cancer	0.000329	0.000739	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—lung cancer	0.000328	0.000736	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—lung cancer	0.000327	0.000734	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—lung cancer	0.000326	0.000733	CcSEcCtD
Plerixafor—Pain—Methotrexate—lung cancer	0.000324	0.000727	CcSEcCtD
Plerixafor—Shock—Doxorubicin—lung cancer	0.000322	0.000725	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—lung cancer	0.000321	0.000722	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—lung cancer	0.000318	0.000715	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ANXA1—lung cancer	0.000317	0.000813	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Doxorubicin—lung cancer	0.000317	0.000712	CcSEcCtD
Plerixafor—CXCR4—Disease—HES1—lung cancer	0.000316	0.000809	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—lung cancer	0.000312	0.000701	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—lung cancer	0.000312	0.000701	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—lung cancer	0.000309	0.000695	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FLT1—lung cancer	0.000307	0.000787	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—lung cancer	0.000304	0.00078	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APP—lung cancer	0.000301	0.00077	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH3—lung cancer	0.000301	0.00077	CbGpPWpGaD
Plerixafor—Urticaria—Methotrexate—lung cancer	0.000301	0.000676	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—lung cancer	0.000299	0.000672	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000299	0.000671	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGF9—lung cancer	0.000298	0.000764	CbGpPWpGaD
Plerixafor—Insomnia—Doxorubicin—lung cancer	0.000296	0.000666	CcSEcCtD
Plerixafor—CXCR4—Disease—ERCC2—lung cancer	0.000295	0.000756	CbGpPWpGaD
Plerixafor—Paraesthesia—Doxorubicin—lung cancer	0.000294	0.000661	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—lung cancer	0.000292	0.000657	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—POMC—lung cancer	0.00029	0.000742	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB3—lung cancer	0.000289	0.00074	CbGpPWpGaD
Plerixafor—Dyspepsia—Doxorubicin—lung cancer	0.000288	0.000648	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JUNB—lung cancer	0.000285	0.00073	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000283	0.000636	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—lung cancer	0.000283	0.000635	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—lung cancer	0.00028	0.00063	CcSEcCtD
Plerixafor—Pain—Doxorubicin—lung cancer	0.00028	0.00063	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—lung cancer	0.000279	0.000627	CcSEcCtD
Plerixafor—CXCR4—Disease—TERT—lung cancer	0.000277	0.000709	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—lung cancer	0.000276	0.000708	CbGpPWpGaD
Plerixafor—Asthenia—Methotrexate—lung cancer	0.000272	0.00061	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—lung cancer	0.00027	0.000607	CcSEcCtD
Plerixafor—CXCR4—Disease—FGFR1—lung cancer	0.000269	0.000688	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—lung cancer	0.000268	0.000602	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—lung cancer	0.000268	0.000602	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—lung cancer	0.000268	0.000686	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIF1A—lung cancer	0.000265	0.000678	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—POMC—lung cancer	0.000263	0.000674	CbGpPWpGaD
Plerixafor—Urticaria—Doxorubicin—lung cancer	0.00026	0.000585	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—lung cancer	0.000259	0.000582	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—lung cancer	0.000259	0.000582	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STK11—lung cancer	0.000259	0.000663	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6R—lung cancer	0.000257	0.000658	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOA1—lung cancer	0.000255	0.000654	CbGpPWpGaD
Plerixafor—Dizziness—Methotrexate—lung cancer	0.00025	0.000562	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FOXO3—lung cancer	0.00025	0.000639	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAP2K1—lung cancer	0.000245	0.000627	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—lung cancer	0.000243	0.000623	CbGpPWpGaD
Plerixafor—Hypersensitivity—Doxorubicin—lung cancer	0.000241	0.000543	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—lung cancer	0.000241	0.000541	CcSEcCtD
Plerixafor—Rash—Methotrexate—lung cancer	0.000239	0.000536	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—lung cancer	0.000238	0.000536	CcSEcCtD
Plerixafor—Headache—Methotrexate—lung cancer	0.000237	0.000533	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—lung cancer	0.000235	0.000528	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AVP—lung cancer	0.000234	0.000599	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—lung cancer	0.000233	0.000598	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—lung cancer	0.000233	0.000597	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KIT—lung cancer	0.000233	0.000597	CbGpPWpGaD
Plerixafor—Pruritus—Doxorubicin—lung cancer	0.000232	0.000521	CcSEcCtD
Plerixafor—CXCR4—Disease—EGF—lung cancer	0.000231	0.00059	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—lung cancer	0.000225	0.000577	CbGpPWpGaD
Plerixafor—Nausea—Methotrexate—lung cancer	0.000225	0.000505	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—lung cancer	0.000224	0.000504	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—lung cancer	0.000224	0.000574	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HES1—lung cancer	0.000221	0.000567	CbGpPWpGaD
Plerixafor—CXCR4—Disease—BRAF—lung cancer	0.000219	0.000562	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RAF1—lung cancer	0.000217	0.000556	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—lung cancer	0.000217	0.000487	CcSEcCtD
Plerixafor—CXCR4—Disease—IL6R—lung cancer	0.000217	0.000555	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CREBBP—lung cancer	0.000216	0.000554	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—lung cancer	0.000214	0.000549	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—lung cancer	0.000212	0.000543	CbGpPWpGaD
Plerixafor—Vomiting—Doxorubicin—lung cancer	0.000208	0.000468	CcSEcCtD
Plerixafor—Rash—Doxorubicin—lung cancer	0.000207	0.000464	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—lung cancer	0.000206	0.000464	CcSEcCtD
Plerixafor—CXCR4—Disease—MAP2K1—lung cancer	0.000206	0.000529	CbGpPWpGaD
Plerixafor—Headache—Doxorubicin—lung cancer	0.000205	0.000461	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3CD—lung cancer	0.000205	0.000525	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—lung cancer	0.000204	0.000521	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB3—lung cancer	0.000202	0.000518	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—lung cancer	0.000195	0.000437	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2—lung cancer	0.000195	0.000498	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—lung cancer	0.000194	0.000497	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR1—lung cancer	0.000188	0.000482	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—lung cancer	0.000185	0.000475	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MDM2—lung cancer	0.000184	0.00047	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RAF1—lung cancer	0.000183	0.000469	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—lung cancer	0.000181	0.000464	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOA1—lung cancer	0.000179	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—lung cancer	0.000179	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—lung cancer	0.000179	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—lung cancer	0.000178	0.000457	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—lung cancer	0.000177	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—lung cancer	0.000177	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—lung cancer	0.000163	0.000418	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KIT—lung cancer	0.000163	0.000418	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—lung cancer	0.000163	0.000418	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—lung cancer	0.000163	0.000418	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGF—lung cancer	0.000161	0.000413	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—lung cancer	0.000156	0.000401	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—POMC—lung cancer	0.000155	0.000398	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—lung cancer	0.000155	0.000396	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—lung cancer	0.000154	0.000396	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—lung cancer	0.000154	0.000393	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6R—lung cancer	0.000152	0.000388	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CREBBP—lung cancer	0.000151	0.000388	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—lung cancer	0.000149	0.000381	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EP300—lung cancer	0.000147	0.000377	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAP2K1—lung cancer	0.000145	0.00037	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—lung cancer	0.000144	0.000368	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—lung cancer	0.000143	0.000367	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—lung cancer	0.000142	0.000364	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—lung cancer	0.000141	0.00036	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—lung cancer	0.000138	0.000354	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—lung cancer	0.000138	0.000353	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—lung cancer	0.000132	0.000338	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—lung cancer	0.000129	0.000331	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MDM2—lung cancer	0.000129	0.000329	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—lung cancer	0.000128	0.000329	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAF1—lung cancer	0.000128	0.000328	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—lung cancer	0.000127	0.000325	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—lung cancer	0.000126	0.000322	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—lung cancer	0.000125	0.000321	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—lung cancer	0.000125	0.000321	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—lung cancer	0.00012	0.000308	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—lung cancer	0.000119	0.000306	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—lung cancer	0.000119	0.000304	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—lung cancer	0.000116	0.000298	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—lung cancer	0.000115	0.000295	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—lung cancer	0.000115	0.000294	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—lung cancer	0.000114	0.000293	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—lung cancer	0.000112	0.000287	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—lung cancer	0.000112	0.000286	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—lung cancer	0.000109	0.000279	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—lung cancer	0.000109	0.000279	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—lung cancer	0.000108	0.000278	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—lung cancer	0.000108	0.000277	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—lung cancer	0.000105	0.00027	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EP300—lung cancer	0.000103	0.000264	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—lung cancer	0.000101	0.000258	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—lung cancer	0.0001	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—lung cancer	9.77e-05	0.00025	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—lung cancer	9.67e-05	0.000248	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—lung cancer	9.65e-05	0.000247	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—lung cancer	9.65e-05	0.000247	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—lung cancer	9.24e-05	0.000237	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—lung cancer	8.99e-05	0.00023	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—lung cancer	8.9e-05	0.000228	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—lung cancer	8.79e-05	0.000225	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—lung cancer	8.3e-05	0.000213	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—lung cancer	7.63e-05	0.000195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—lung cancer	7.38e-05	0.000189	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—lung cancer	7.06e-05	0.000181	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—lung cancer	6.75e-05	0.000173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—lung cancer	6.23e-05	0.00016	CbGpPWpGaD
